PDS Biotechnology Corp
PDSB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001472091
No open-market purchases or sales by PDS Biotechnology Corp insiders were filed in the last 90 days; 52 institutions reported holding it in 13F filings for Q2 2026, worth $6.78M in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding PDS Biotechnology Corp changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 77 | 3 | 57 | −17 |
| Shares | 5.50M | 488.4K | 4.34M | −675.3K (−13.5%) |
| Value | $16.1M | $1.43M | $16.6M | +$1.88M (+12.8%) |
3 institutions that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (7)
Institutions that held PDS Biotechnology Corp at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock, Inc. | 488,296 | $1.87M | 0.00% |
| Sherbrooke Park Advisers LLC | 40,182 | $153.5K | 0.04% |
| Marshall Wace, LLP | 28,187 | $107.7K | 0.00% |
| Renaissance Technologies LLC | 23,200 | $88.6K | 0.00% |
| Ronald Blue Trust, Inc. | 4,500 | $13.2K | 0.00% |
| Truvestments Capital LLC | 1,111 | $4.24K | 0.00% |
| National Bank of Canada | 1 | $4 | 0.00% |
Sold out (24)
Institutions that held PDS Biotechnology Corp at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Goldman Sachs Group Inc | 317,460 | $930.2K |
| Sofinnova Investments, Inc. | 142,635 | $417.9K |
| Jane Street Group, LLC | 114,032 | $334.1K |
| Alpine Global Management, LLC | 75,000 | $219.8K |
| Centiva Capital, LP | 47,966 | $140.5K |
| Y-Intercept (Hong Kong) Ltd | 45,883 | $134.4K |
| Squarepoint Ops LLC | 40,979 | $120.1K |
| HRT Financial LP | 38,107 | $111.0K |
| Paloma Partners Management Co | 31,525 | $92.4K |
| Ground Swell Capital, LLC | 22,700 | $66.5K |
| AQR Capital Management LLC | 22,156 | $64.9K |
| Schonfeld Strategic Advisors LLC | 15,400 | $45.1K |
| Close Asset Management Ltd | 15,000 | $44.0K |
| Mirae Asset Global ETFs Holdings Ltd. | 14,643 | $42.9K |
| Rhumbline Advisers | 11,537 | $33.8K |
| EP Wealth Advisors, LLC | 10,207 | $29.9K |
| Group One Trading, L.P. | 8,481 | $24.8K |
| Macquarie Group Ltd | 1,420 | $4.16K |
| New York State Common Retirement Fund | 224 | $656 |
| Rothschild Investment LLC | 45 | $132 |
| Northwestern Mutual Wealth Management Co | 28 | $82 |
| Mather Group, LLC. | 10 | $40 |
| Barclays PLC | 1 | $3 |
| CWM, LLC | 42 | $0 |
Not filed for Q3 2024 yet (3)
Institutions that held PDS Biotechnology Corp at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 486,967 | $1.43M |
| ICA Group Wealth Management, LLC | 1,100 | $3.22K |
| JJJ Advisors Inc. | 287 | $841 |